vs
STANDARD BIOTOOLS INC.（LAB）与Valens Semiconductor Ltd.（VLN）财务数据对比。点击上方公司名可切换其他公司
STANDARD BIOTOOLS INC.的季度营收约是Valens Semiconductor Ltd.的1.1倍（$19.6M vs $17.3M），Valens Semiconductor Ltd.净利率更高（-42.2% vs -177.4%，领先135.2%），Valens Semiconductor Ltd.同比增速更快（8.1% vs -11.5%），Valens Semiconductor Ltd.自由现金流更多（$-4.9M vs $-23.1M）
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
瓦伦斯半导体是一家总部位于以色列的无晶圆厂半导体企业，核心产品面向汽车与音视频行业，主打未压缩超高清多媒体内容传输及车内连接应用场景。作为MIPI联盟成员，该公司率先推出了符合MIPI A-PHY标准的商用芯片组，同时也是HDBaseT技术的发明者。
LAB vs VLN — 直观对比
营收规模更大
LAB
是对方的1.1倍
$17.3M
营收增速更快
VLN
高出19.6%
-11.5%
净利率更高
VLN
高出135.2%
-177.4%
自由现金流更多
VLN
多$18.1M
$-23.1M
损益表 — Q3 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $19.6M | $17.3M |
| 净利润 | $-34.7M | $-7.3M |
| 毛利率 | 48.5% | 63.0% |
| 营业利润率 | -168.5% | -46.4% |
| 净利率 | -177.4% | -42.2% |
| 营收同比 | -11.5% | 8.1% |
| 净利润同比 | -28.8% | 29.3% |
| 每股收益（稀释后） | $-0.09 | $-0.07 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LABVLN
| Q3 25 | $19.6M | $17.3M | ||
| Q2 25 | $21.8M | $17.1M | ||
| Q1 25 | $40.8M | $16.8M | ||
| Q3 24 | $22.1M | $16.0M | ||
| Q2 24 | $22.5M | $13.6M | ||
| Q1 24 | $45.5M | — | ||
| Q4 23 | $28.2M | — | ||
| Q3 23 | $25.4M | — |
净利润LABVLN
| Q3 25 | $-34.7M | $-7.3M | ||
| Q2 25 | $-33.5M | $-7.2M | ||
| Q1 25 | $-26.0M | $-8.3M | ||
| Q3 24 | $-26.9M | $-10.4M | ||
| Q2 24 | $-45.7M | $-8.9M | ||
| Q1 24 | $-32.2M | — | ||
| Q4 23 | $-19.8M | — | ||
| Q3 23 | $-21.0M | — |
毛利率LABVLN
| Q3 25 | 48.5% | 63.0% | ||
| Q2 25 | 48.8% | 63.5% | ||
| Q1 25 | 48.4% | 62.9% | ||
| Q3 24 | 54.9% | 56.4% | ||
| Q2 24 | 46.1% | 61.4% | ||
| Q1 24 | 53.1% | — | ||
| Q4 23 | 47.6% | — | ||
| Q3 23 | 44.0% | — |
营业利润率LABVLN
| Q3 25 | -168.5% | -46.4% | ||
| Q2 25 | -118.1% | -43.3% | ||
| Q1 25 | -80.8% | -56.2% | ||
| Q3 24 | -120.9% | -76.3% | ||
| Q2 24 | -134.5% | -69.2% | ||
| Q1 24 | -132.2% | — | ||
| Q4 23 | -75.9% | — | ||
| Q3 23 | -83.5% | — |
净利率LABVLN
| Q3 25 | -177.4% | -42.2% | ||
| Q2 25 | -153.7% | -42.1% | ||
| Q1 25 | -63.8% | -49.4% | ||
| Q3 24 | -122.0% | -64.6% | ||
| Q2 24 | -203.3% | -65.2% | ||
| Q1 24 | -70.6% | — | ||
| Q4 23 | -70.2% | — | ||
| Q3 23 | -82.8% | — |
每股收益（稀释后）LABVLN
| Q3 25 | $-0.09 | $-0.07 | ||
| Q2 25 | $-0.09 | $-0.07 | ||
| Q1 25 | $-0.07 | $-0.08 | ||
| Q3 24 | $-0.07 | $-0.10 | ||
| Q2 24 | $-0.12 | $-0.08 | ||
| Q1 24 | $-0.27 | — | ||
| Q4 23 | $-0.24 | — | ||
| Q3 23 | $-0.27 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $129.4M | $93.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $399.7M | $108.8M |
| 总资产 | $539.6M | $136.7M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资LABVLN
| Q3 25 | $129.4M | $93.5M | ||
| Q2 25 | $158.6M | $102.7M | ||
| Q1 25 | $150.9M | $112.5M | ||
| Q3 24 | $210.6M | $133.1M | ||
| Q2 24 | $269.8M | $105.9M | ||
| Q1 24 | $287.1M | — | ||
| Q4 23 | $51.7M | — | ||
| Q3 23 | $79.7M | — |
总债务LABVLN
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | $55.2M | — | ||
| Q2 24 | $55.1M | — | ||
| Q1 24 | $55.0M | — | ||
| Q4 23 | $63.5M | — | ||
| Q3 23 | $64.6M | — |
股东权益LABVLN
| Q3 25 | $399.7M | $108.8M | ||
| Q2 25 | $424.5M | $116.5M | ||
| Q1 25 | $454.6M | $128.6M | ||
| Q3 24 | $489.3M | $147.0M | ||
| Q2 24 | $510.3M | $153.5M | ||
| Q1 24 | $577.3M | — | ||
| Q4 23 | $-148.1M | — | ||
| Q3 23 | $-131.7M | — |
总资产LABVLN
| Q3 25 | $539.6M | $136.7M | ||
| Q2 25 | $557.0M | $144.8M | ||
| Q1 25 | $579.6M | $154.6M | ||
| Q3 24 | $681.5M | $171.9M | ||
| Q2 24 | $708.7M | $175.8M | ||
| Q1 24 | $777.7M | — | ||
| Q4 23 | $323.1M | — | ||
| Q3 23 | $339.3M | — |
负债/权益比LABVLN
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | 0.11× | — | ||
| Q2 24 | 0.11× | — | ||
| Q1 24 | 0.10× | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-22.2M | $-4.7M |
| 自由现金流经营现金流 - 资本支出 | $-23.1M | $-4.9M |
| 自由现金流率自由现金流/营收 | -118.1% | -28.5% |
| 资本支出强度资本支出/营收 | 4.5% | 1.6% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-111.1M | $-11.0M |
8季度趋势，按日历期对齐
经营现金流LABVLN
| Q3 25 | $-22.2M | $-4.7M | ||
| Q2 25 | $-20.7M | $-211.0K | ||
| Q1 25 | $-30.3M | $-7.6M | ||
| Q3 24 | $-27.9M | $3.0M | ||
| Q2 24 | $-39.0M | $-225.0K | ||
| Q1 24 | $-62.5M | — | ||
| Q4 23 | $-14.1M | — | ||
| Q3 23 | $-11.4M | — |
自由现金流LABVLN
| Q3 25 | $-23.1M | $-4.9M | ||
| Q2 25 | $-22.6M | $-330.0K | ||
| Q1 25 | $-35.3M | $-8.0M | ||
| Q3 24 | $-30.1M | $2.2M | ||
| Q2 24 | $-41.0M | $-460.0K | ||
| Q1 24 | $-63.3M | — | ||
| Q4 23 | $-14.1M | — | ||
| Q3 23 | $-12.3M | — |
自由现金流率LABVLN
| Q3 25 | -118.1% | -28.5% | ||
| Q2 25 | -103.6% | -1.9% | ||
| Q1 25 | -86.6% | -47.3% | ||
| Q3 24 | -136.4% | 14.0% | ||
| Q2 24 | -182.2% | -3.4% | ||
| Q1 24 | -138.9% | — | ||
| Q4 23 | -50.2% | — | ||
| Q3 23 | -48.6% | — |
资本支出强度LABVLN
| Q3 25 | 4.5% | 1.6% | ||
| Q2 25 | 8.7% | 0.7% | ||
| Q1 25 | 12.4% | 2.1% | ||
| Q3 24 | 10.2% | 4.5% | ||
| Q2 24 | 8.6% | 1.7% | ||
| Q1 24 | 1.7% | — | ||
| Q4 23 | 0.3% | — | ||
| Q3 23 | 3.6% | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
VLN
暂无分部数据
